Compare Consolidated Edison, Inc. (ED) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Enveric Biosciences Inc — how do they compare? Consolidated Edison, Inc. trades at $106.1 (market cap $39.20B), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: Consolidated Edison, Inc. is far larger — about 5764.7× Enveric Biosciences Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Enveric Biosciences Inc for 14 Days on average.
| ED | ENVB | |
|---|---|---|
Market Cap | $39.20B | $6.80M |
Volume | 2,142,900 | 64,867 |
Sector | Utilities | Health |
52-Week High | $115.46 | $10.80 |
52-Week Low | $95.37 | $1.27 |
Typical Hold Time | 75 Days | 14 Days |
Enterprise Value | $66.05B | -$1.49M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $106.10, up 1.39% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The stock's valuation appears reasonable with a P/E of 17.43 and P/S of 2.18, while profitability metrics like a 12.53% net income margin and 8.96% ROE reflect steady utility performance. Recent earnings showed beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains strong cash flow from operations of $4.80 billion in 2025 and continues its dividend aristocrat status with a recent $0.89 dividend declaration.
ED offers stable income appeal with a solid dividend history, supported by regulated utility operations and a $24.8 billion economic impact in New York. However, high debt levels ($24.65 billion long-term) and modest growth prospects pose risks. Analyst sentiment is cautious with 62.96% hold ratings, though the consensus price target of $106.33 aligns with the current price, suggesting limited near-term upside amid economic sensitivity.
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
